- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Prozac, Sarafem
Synonyms :
Class :
Antidepressants and antianxiety drugs; Selective Serotonin Reuptake Inhibitors
Dosage forms & Strengths:
Adult:
Tablet:
10 mg
20 mg
60 mg
Capsule:
10 mg
20 mg
40 mg
90 mg
20 mg orally each day
Increase the dose by 20 mg/day every week
Do not exceed the dose of more than 80 mg orally each day
90 mg of a delayed-release capsule can be taken each week orally
Indicated for depression because of Bipolar I Disorder
Initially, 20 mg fluoxetine with 5 mg olanzapine orally every evening
Dose Adjustment
According to the tolerance and efficacy, take 20-50 mg of fluoxetine and 5-12.5 mg of olanzapine
20 mg orally each day
Increase the dose by 20 mg/day
Do not exceed the dose of more than 80 mg orally each day
Take a 90 mg delayed-release capsule orally each week
Initially, 60 mg orally each day for several days
The maintenance dose can be titrated
10 mg orally each day for the first week; later, 20 mg orally each day
Increase the dose gradually after several weeks
Do not exceed the dose of more than 60 mg each day
10 mg/day orally each day
Increase the dose by 10-20 mg/day after several weeks according to tolerance
Unless sedation occurs, do not take the medication at night
10 mg orally each day
Increase the dose to 20 mg/day after a week
Maintain the lowest effective dose
Assess the need for extended therapy if required
For more than eight years- Initially, 20 mg orally each day
Start the dose at 10 mg/day in children with less weight
Do not exceed the dose of more than 20 mg orally each day
10 mg orally each day
Increase the dose to 20 mg/day after 2 weeks
For obese children and adolescents- 20-60 mg each day
For lower-weight children- 20-30 mg each day
10 mg/day orally each day
Increase the dose by 10-20 mg/day after several weeks according to tolerance
Unless sedation occurs, do not take the medication at night
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
it may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
may have an increased antiplatelet effect when combined with NSAIDs
May increase the hypoglycemic effect of each other when combined
CYP2D6 Inhibitors increase the concentration of doxorubicin in serum
it increases the effect of SSRIs
CYP2C19 Inhibitors increase the concentration of mavacamten in serum
they increase the effect of SSRIs
they increase the effect of SSRIs
they increase the effect of SSRIs
they increase the effect of SSRIs
they increase the effect of SSRIs
CYP2C19 Inhibitors increase the concentration of pimozide in serum
it increases the effect of SSRIs
fluoxetine increases the concentration of thioridazine in the serum
anticoagulant agents have a synergistic effect on urokinase
may have an increasingly adverse effect when combined with selective serotonin reuptake inhibitors
may have an increased risk of adverse effects when combined with fluoxetine
QTc interval is increased both by lenvatinib and fluoxetine
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
May have an increased serotonergic effect when combined with Serotonin/Norepinephrine Reuptake Inhibitors
may have an increased risk of adverse effects when combined with fluoxetine
it increases the toxicity of SSRIs
it increases the toxicity of SSRIs
it increases the effect of SSRIs
it increases the effect of SSRIs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
SSRIs increase the antiplatelet effect of NSAIDs
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
may have an increased risk of hypoglycemia when combined with fluoxetine
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
SSRIs increase the CNS depressing effect of brexanolone
antiplatelet agents increase the toxicity of edoxaban
it increases the toxicity of antiplatelet agents
CYP2D6 inhibitors increase the concentration of aripiprazole
antiplatelet agents increase the effect of anticoagulation of bemiparin
antiplatelet agents increase the effect of anticoagulation of bemiparin
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of Agents with blood Glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect of agents with blood glucose lowering effects
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
it may diminish the therapeutic efficacy when combined with castor oil
Combining fluoxetine with pranlukast may cause a reduction in the fluoxetine’s metabolism
when ajmaline is used together with fluoxetine, the risk or seriousness of QTc prolongation is enhanced
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, both increase the QTC interval
it may increase the effect of other selective serotonin reuptake inhibitors
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K
may enhance the toxicity of the other through anti coagulation
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the antiplatelet effect
may increase the hyponatremic effect of thiazide and thiazide-like diuretics
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the toxic effect of antipsychotic agents
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the effect of SSRI
may enhance the risk of adverse effects
